328 related articles for article (PubMed ID: 17610338)
1. A cost-effectiveness analysis of first-line controller therapies for persistent asthma.
Shih YC; Mauskopf J; Borker R
Pharmacoeconomics; 2007; 25(7):577-90. PubMed ID: 17610338
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma.
O'Connor RD; Nelson H; Borker R; Emmett A; Jhingran P; Rickard K; Dorinsky P
Pharmacoeconomics; 2004; 22(12):815-25. PubMed ID: 15294013
[TBL] [Abstract][Full Text] [Related]
3. Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma.
Lyseng-Williamson KA; Plosker GL
Pharmacoeconomics; 2003; 21(13):951-89. PubMed ID: 12959627
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma.
Sheth K; Borker R; Emmett A; Rickard K; Dorinsky P
Pharmacoeconomics; 2002; 20(13):909-18. PubMed ID: 12381242
[TBL] [Abstract][Full Text] [Related]
5. COST-effectiveness of salmeterol/fluticasone propionate combination (Advair(®)) in uncontrolled asthma in Canada.
Ismaila AS; Risebrough N; Li C; Corriveau D; Hawkins N; FitzGerald JM; Su Z
Respir Med; 2014 Sep; 108(9):1292-302. PubMed ID: 25175480
[TBL] [Abstract][Full Text] [Related]
6. Salmeterol/fluticasone propionate versus fluticasone propionate plus montelukast: a cost-effective comparison for asthma.
Pieters WR; Wilson KK; Smith HC; Tamminga JJ; Sondhi S
Treat Respir Med; 2005; 4(2):129-38. PubMed ID: 15813665
[TBL] [Abstract][Full Text] [Related]
7. Inhaled salmeterol/fluticasone propionate combination. A pharmacoeconomic review of its use in the management of asthma.
Markham A; Adkins JC
Pharmacoeconomics; 2000 Dec; 18(6):591-608. PubMed ID: 11227397
[TBL] [Abstract][Full Text] [Related]
8. Development of an economic model to assess the cost effectiveness of asthma management strategies.
Price MJ; Briggs AH
Pharmacoeconomics; 2002; 20(3):183-94. PubMed ID: 11929348
[TBL] [Abstract][Full Text] [Related]
9. [Cost effectiveness of treatment with salmeterol/fluticasone compared to montelukast for the control of persistent asthma in children].
Rely K; McQuire SE; Alexandre PK; Escudero GS
Value Health; 2011; 14(5 Suppl 1):S43-7. PubMed ID: 21839898
[TBL] [Abstract][Full Text] [Related]
10. Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs.
O'Connor RD; Stanford R; Crim C; Yancey SW; Edwards L; Rickard KA; Dorinsky P
Ann Allergy Asthma Immunol; 2004 Dec; 93(6):581-8. PubMed ID: 15609769
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD.
Earnshaw SR; Wilson MR; Dalal AA; Chambers MG; Jhingran P; Stanford R; Mapel DW
Respir Med; 2009 Jan; 103(1):12-21. PubMed ID: 19010652
[TBL] [Abstract][Full Text] [Related]
12. Inhaled fluticasone propionate. A pharmacoeconomic review of its use in the management of asthma.
Lamb HM; Culy CR; Faulds D
Pharmacoeconomics; 2000 Nov; 18(5):487-510. PubMed ID: 11151402
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 microg twice daily and budesonide 800 microg twice daily in the treatment of adults and adolescents with asthma. International Study Group.
Lundbäck B; Jenkins C; Price MJ; Thwaites RM
Respir Med; 2000 Jul; 94(7):724-32. PubMed ID: 10926346
[TBL] [Abstract][Full Text] [Related]
14. Treatment options for initial maintenance therapy of persistent asthma: a review of inhaled corticosteroids and leukotriene receptor antagonists.
Creticos PS
Drugs; 2003; 63 Suppl 2():1-20. PubMed ID: 14984077
[TBL] [Abstract][Full Text] [Related]
15. Cost-efficacy analysis of fluticasone propionate versus zafirlukast in patients with persistent asthma.
Menendez R; Stanford RH; Edwards L; Kalberg C; Rickard K
Pharmacoeconomics; 2001; 19(8):865-74. PubMed ID: 11596838
[TBL] [Abstract][Full Text] [Related]
16. Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma.
Markham A; Jarvis B
Drugs; 2000 Nov; 60(5):1207-33. PubMed ID: 11129128
[TBL] [Abstract][Full Text] [Related]
17. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease.
Spencer M; Briggs AH; Grossman RF; Rance L
Pharmacoeconomics; 2005; 23(6):619-37. PubMed ID: 15960557
[TBL] [Abstract][Full Text] [Related]
18. Outcomes associated with initiation of different controller therapies in a Medicaid asthmatic population: a retrospective data analysis.
Balkrishnan R; Nelsen LM; Kulkarni AS; Pleasants RA; Whitmire JT; Schechter MS
J Asthma; 2005 Feb; 42(1):35-40. PubMed ID: 15801326
[TBL] [Abstract][Full Text] [Related]
19. Initial treatment of symptomatic mild to moderate bronchial asthma with the salmeterol/fluticasone propionate (50/250 microg) combination product (SAS 40023).
Baumgarten C; Geldszus R; Behre U; Peslis N; Trautmann M;
Eur J Med Res; 2002 Jan; 7(1):1-7. PubMed ID: 11827834
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of fluticasone propionate and flunisolide in the treatment of corticosteroid-naive patients with moderate asthma.
Volmer T; Kielhorn A; Weber HH; Wiessmann KJ
Pharmacoeconomics; 1999 Nov; 16(5 Pt 2):525-31. PubMed ID: 10662477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
